** Shares of EyePoint Pharmaceuticals rise 36.5% to five-month high of $12.96
** Co says its drug, Duravyu, showed an improvement in how well patients can see objects at a distance in a mid-stage trial testing it in diabetic macular edema $(DME.AU)$
** DME is an eye condition that causes blurry vision in people with diabetes
** Co expects to report the full topline results in Q1 2025
** Including session's move, EYPT stock down 50.8% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.